← 프로그램 목록
ADCPhase 2Recruiting

Fixed dose (Patritumab Deruxtecan)

Daiichi Sankyo

비교

Patritumab Deruxtecan (Fixed dose)(Daiichi Sankyo)은 Non-Small Cell Lung Cancer Metastatic 표적 ADC로, Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 영역에서 개발·상용화 중입니다. 작용기전: inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64% (ClinicalTrials.gov NCT04619004). PK: t½ 53 h. 차별점: novel formulation approach showed proven quality characteristics for specific use in coagulopathy associated with SARS-CoV-2.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

Non-Small Cell Lung Cancer Metastatic

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)

CAR-T Cell Therapy: Development of an Efficient Sampling Strategy

novel formulation approach showed proven quality characteristics for specific use in coagulopathy associated with SARS-CoV-2

Mechanism of Action

inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor

Apoptosis and Synergizes with Bortezomib via ER Stress Mediated Ubiquitination of GRP78 in T-Cell Acute Lymphoblastic Leukemia

Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 88건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 2 · Phase 3 · N/A
  • Status: No longer available · Recruiting · Completed
  • 주요 endpoint: Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. · Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB). · To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms. · To determine incidence of adverse events (AEs) · serious adverse events (SAEs)
  • 등록된 결과: ORR 64%
  • PFS: 5.5
  • 핵심: This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or lo…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Patritumab Deruxtecan (Fixed dose)은 어떤 치료제인가요?
Patritumab Deruxtecan (Fixed dose)(Daiichi Sankyo)은 Non-Small Cell Lung Cancer Metastatic 표적 ADC로, Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Patritumab Deruxtecan (Fixed dose)의 임상 단계는?
Patritumab Deruxtecan (Fixed dose)의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.